Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.
TL;DR: Both combination therapies in patients with suboptimal response to adefovir led to a significant decrease in HBV DNA and HBeAg serological outcomes were higher with telbivudine plus ADV combination therapy.
Journal ArticleDOI
Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
Annikki de Niet,Louis Jansen,Hans L. Zaaijer,Ursula Klause,B. Takkenberg,Harry L.A. Janssen,Tom Chu,Rosemary Petric,Hendrik W. Reesink +8 more
TL;DR: It is demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in H beAg-positive CHB patients treated with pegylated interferon and adefovir.
Journal ArticleDOI
Histological improvement of long‐term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels
TL;DR: Long‐term antiviral treatment could achieve significant histological improvement in CHB patients with fibrosis or cirrhosis, regardless of ALT level, according to the Scheuer scoring system.
Journal ArticleDOI
Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.
Jun Cheng,Yuming Wang,Jinlin Hou,Duande Luo,Qing Xie,Qin Ning,Hong Ren,Huiguo Ding,Jifang Sheng,Lai Wei,Shijun Chen,Xiaoling Fan,Wenxiang Huang,Chen Pan,Zhiliang Gao,Jiming Zhang,Boping Zhou,Guofeng Chen,Mobin Wan,Hong Tang,Guiqiang Wang,Yuxiu Yang,Rosmawati Mohamed,Richard Guan,Tzong-Hsi Lee,Wen-Hsiung Chang,Huang Zhenfei,Zhang Ye,Dao-Zhen Xu +28 more
TL;DR: In Chinese patients with HBeAg-positive chronic hepatitis B, PEG-IFN alfa-2b 1.5μg/kg/wk for 48 weeks is more efficacious compared with 1.0 and 1.4μg-kg/week for 24 weeks.
Journal ArticleDOI
High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
Hee Bok Chae,Mee Jin Kim,Eui Geun Seo,Yong Hyeok Choi,Hee Seung Lee,Joung-Ho Han,Soon Man Yoon,Seon Mee Park,Sei Jin Youn +8 more
TL;DR: AD+ETV combination therapy induced a good IVR in CHB patients who were refractory to more than 2 antiviral agents and may be a good alternative to TDF in Korea, where that drug is not available.